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Technology adoption and
implementation in organisations:
comparative case studies of 12 English
NHS Trusts
Yiannis Kyratsis, Raheelah Ahmad, Alison Holmes
ABSTRACT
Objectives: To understand organisational technology
adoption (initiation, adoption decision,
implementation) by looking at the different types of
innovation knowledge used during this process.
Design: Qualitative, multisite, comparative case study
design.
Setting: One primary care and 11 acute care
organisations (trusts) across all health regions in
England in the context of infection prevention and
control.
Participants and data analysis: 121 semistructured
individual and group interviews with 109 informants,
involving clinical and non-clinical staff from all
organisational levels and various professional groups.
Documentary evidence and field notes were also used.
38 technology adoption processes were analysed
using an integrated approach combining inductive and
deductive reasoning.
Main findings: Those involved in the process variably
accessed three types of innovation knowledge:
‘awareness’ (information that an innovation exists),
‘principles’ (information about an innovation’s
functioning principles) and ‘how-to’ (information
required to use an innovation properly at individual and
organisational levels). Centralised (national,
government-led) and local sources were used to obtain
this knowledge. Localised professional networks were
preferred sources for all three types of knowledge.
Professional backgrounds influenced an asymmetric
attention to different types of innovation knowledge.
When less attention was given to ‘how-to’ compared
with ‘principles’ knowledge at the early stages of the
process, this contributed to 12 cases of incomplete
implementation or discontinuance after initial
adoption.
Conclusions: Potential adopters and change agents
often overlooked or undervalued ‘how-to’ knowledge.
Balancing ‘principles’ and ‘how-to’ knowledge early in
the innovation process enhanced successful
technology adoption and implementation by
considering efficacy as well as strategic, structural and
cultural fit with the organisation’s context. This
learning is critical given the policy emphasis for health
organisations to be innovation-ready.
INTRODUCTION
The recent focus on quality and efficiency in
healthcare by policy makers1 highlights the
need to harness new healthcare technologies
and innovation to improve quality of patient
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ARTICLE SUMMARY
Article focus
- Despite policy support and the development of
a dedicated evidence dissemination infrastruc-
ture in the NHS, why is technology adoption and
implementation still a challenge?
- We need to understand better how the innovation
process unfolds in organisations to build on what
we know about individual behaviours. In partic-
ular, how the use of different types of knowledge
about an innovation impacts its adoption and
implementation.
Key messages
- In our study, centralised dissemination of
evidence had minimal to moderate impact on
organisational innovation adoption decisions.
Practice-based, peer-mediated and local dissem-
ination systems were perceived more relevant.
- In contrast to technology adoption by individuals,
organisational adoption required a wider multi-
faceted conceptualisation of ‘how-to’ knowledge
in line with the more complex dynamics in
organisations. When ‘how-to’ knowledge was
undervalued and considered late, important
strategic, structural and cultural elements of the
trust’s context were overlooked. This had
negative implications for technology adoption
and implementation.
- Professional backgrounds of those involved in
the process influenced the types of innovation
knowledge considered, which had implications
for implementation. The involvement of diverse
professionals in decision-making improves the
chances of successful implementation through
a balanced consideration of the strength of
scientific evidence and practical application.
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care and health system productivity.2 3 The uptake and
implementation of new technologies in healthcare has
often proved challenging and in some cases very slow.4e6
In the UK, the significant ‘research to practice’ knowl-
edge gap and the suboptimal implementation of new
ideas and technologies into clinical practice have been
emphasised in several recent policy documents.7e9
Policy and academic systematic reviews6 10 consistently
show that there remains a poor understanding of the
mechanisms and processes that encourage the adoption
of new interventions. Specifically, attention to the
processes by which organisational members access and
use implementation and clinical evidence during deci-
sion-making is required.9 11 As regards technology
adoption in the NHS, a recent systematic review12 has
found that there has been little research in this area.
In the last decade, government-funded agencies have
been created to encourage innovation uptake and
promote the use of evidence-based innovations in the
NHS1 13; such predominately centralised evidence
dissemination structures include the NHS Institute for
Innovation and Improvement, the National Institute for
Health and Clinical Excellence with the launch of the
NHS Evidence online portal and the NHS Technology
Adoption Centre, which works to speed-up the adoption
of proven technologies by NHS organisations. Despite
these initiatives, the challenges of adopting novel
technologies in the NHS persist.
Our study addresses this research gap and is well
grounded in innovation change and diffusion theo-
ries.14e16 Specifically, our study unpacks the innovation
processes in organisationsdin contrast to individualsd
by investigating in detail the interplay between the types
and sources of innovation knowledge used. We empiri-
cally focus our investigation on infection prevention and
control (IPC) as it represents a cross-cutting priority area
in healthcare with application to primary and acute care,
surgery and medicine alike. While there has been
increasing public and policy attention to address
healthcare-associated infections (HCAIs) (box 1), the
uptake and implementation of new technologies in IPC
varies and remains slow.24 This empirical setting, there-
fore, offers opportunities to generate transferable
lessons.
METHODS
Design and theoretical approach
This article reports on findings from a larger innovation
adoption study in the area of HCAIs commissioned by
the Department of Health (DH).25 We employed
a multiple case study research design to build theory
inductively26 covering the decision-making, procure-
ment and implementation processes by NHS organisa-
tions when introducing innovative technologies. We
undertook comparative case studies27 across 12 NHS
trusts in England with each trust and technology adop-
tion decisions as units of analysis. Consistent with our
research aims, we employed interpretive methods of
enquiry, which allows description, interpretation and
explanation of a phenomenon rather than estimation of
its prevalence.28
Damanpour and Schneider14 suggest that the process
of innovation adoption in organisations can be divided
into three broad phases of ‘pre-adoption’, ‘adoption
decision’ and ‘post-adoption’, also referred to in the
ARTICLE SUMMARY
Strengths and limitations of this study
- The scale of the study, its real time and longitudinal nature
provide a rich data set. Our study is theory driven and
comprises multisite comparative case studies, which enhance
the generalisability of findings beyond the context of the
studied trusts.
- We explicitly studied cases of non-adoption and discontinua-
tion after initial adoption to provide important learning often
missing from innovation diffusion research.
- On limitations, we were not able to follow implementation past
the end of August 2010 and therefore do not have information
on routinised use of the implemented technologies.
Box 1 Healthcare-associated infections (HCAIs) initiatives in the NHS
HCAIs are a worldwide problem causing high mortality and morbidity with significant cost implications for health systems.17e22
Both developing and more developed countries face the challenge,18 and there is intense media and public attention on the
issue. In the UK, a range of infection prevention and control policies have been introduced to help tackle the problem, including
legislation, performance targets and clinical guidelines. In England, the reporting of meticillin-resistant Staphylococcus aureus
bloodstream infections and Clostridium difficile infections are mandatory, and there are national and local targets for reduction
as well as national evidence-based guidelines.23 The development of effective technology interventions to complement good
infection control practice is viewed as central to tackling HCAIs, and a range of evidence-based innovations have been
developed. Government-funded programmes, such as the Department of Health ‘HCAI Technology Innovation Programme’,24
have been created to fast-track the innovation process. Programme work streams span development to procurement and
implementation processes and include: ‘Smart Ideas’, ‘Design Bugs Out’, ‘Smart Solutions’, ‘Product Surgeries’ and ‘Showcase
Hospitals’, the latter focusing on the in-use value of HCAI technologies. In addition, the Health Protection Agency Rapid Review
Panel was set up in 2004 to review new HCAI-related technologies providing a prompt assessment of new and novel equipment,
materials and other products or protocols that may be of value to the NHS to help reduce HCAI rates; recommendation
statements about the novel products are given to suppliers and NHS bodies (‘Recommendation 1’ being the highest,
encouraging adoption by the NHS).
2 Kyratsis Y, Ahmad R, Holmes A. BMJ Open 2012;2:e000872. doi:10.1136/bmjopen-2012-000872
Technology adoption and implementation in organisations
literature as ‘initiation’, ‘adoption (decision)’ and
‘implementation’.13 15 26 In this article, we use the latter
terminology. Adoption is viewed as a process in which
organisational members analyse the potential benefits
and negative aspects of an innovation on the basis of
gathered knowledge. During this process, three types of
innovation knowledge are important in moving potential
adopters from ‘ignorance’ through awareness, attitude
formation, evaluation and on to adoptiond‘the decision
to make full use of the innovation as the best course of
action available’15:
1. Awareness knowledgedthe awareness that an
innovation exists and knowledge of its key properties.
2. How-to knowledgedthe information necessary to use
an innovation properly.
3. Principles knowledgedinformation dealing with the
functioning principles underlying how the innovation
works.
The above definitions of innovation knowledge may be
relatively simple and consistent when applied to tech-
nology adoption by individuals, while they become
ambiguous when applied to the organisational setting in
which the process is complex and contested.12 29
Evidence is a form of knowledge and in this article
comprises empirical, theoretical and experiential ways of
knowing.30
Sampling and settings
The study comprised one primary and 11 acute care
organisations (NHS trusts), across all 10 Strategic Health
Authorities in England. The trusts included in the study
sample were diverse in geography, size and type
(table 1). The sample was predefined with one attribute
in common as recipients of DH’s ‘HCAI Technology
Innovation Award for outstanding contributions to
fighting infections 2009’. The trusts were nominated by
each Strategic Health Authority on the basis of having
excelled in either turnaround or ‘best in class’
concerning infection prevention performance in the
fiscal year 2008/2009. The trusts were given free reign to
use the sum to procure technologies that could help
reduce HCAIs (awarded in February 2009).
Data collection and participants
We collected data from secondary sources to provide
a historical dimension to better situate the studied
decision-making processes.
Data from primary sources comprised 121 semi-
structured individual and group interviews carried out
during the 18 months (July 2009eAugust 2010). On
average, this equates to 10 hour-long interviews per trust.
Twelve informants were interviewed more than once.
Depending on the number and scope of technologies,
we conducted between two to five visits per trust. Within
each of the trust sites, we purposively sampled a diverse
range of informants involved in the technology adoption
or implementation, reflecting various perspectives,
professional and organisational roles. Our participants
included clinical and non-clinical managers, members of
trusts’ executive boards, health professionals, staff from
estates and facilities and IPC teams comprising: Director
of Infection Prevention & Control (DIPC), deputy DIPC,
medical microbiologist, infection doctor, infection
control nurses (the most populous group), surveillance
staff, decontamination lead. Some IPC teams included
a pharmacist or infection control matrons.
Interviews explored individuals’ perceptions, experi-
ences and views on the technology selection decisions,
procurement and implementation processes. In the first
visit, the ongoing decision-making process was captured,
and in follow-up visits, technology selection outcome
and implementation experiences were explored. Field
notes were taken during observation of technologies in-
use and relevant meetings. Observation was used to
familiarise with technologies and context, and triangu-
late interview data. For example, in one trust,
Table 1 Case study sites characteristics
Trust Trust type
Number of
beds
Population
covered (m)
Financial
turnover (m)
Number of
sites
DIPC
profession
Number of
technologies
adopted
T1 S, PFI 1269 0.75 £400 Multisite Medical doctor 1
T2 S, F, PFI 754 0.34 £156 Multisite Medical doctor 6
T3 T, U 1902 1 (S), 3 (T) £652 Multisite Medical doctor 1
T4 T, U, (PFI) 988 0.5 (S), 1.5 m (T) £420 Multisite Medical doctor 3
T5 T, U, F, (PFI) 2068 0.5 (S), 1.7 (T) £648 Multisite Medical doctor 3
T6 S, PFI 1095 0.6 £430 Multisite Medical doctor 2
T7 S, F, (PFI) 602 0.35 £200 One site Medical doctor 4
T8* T, U, F 807 0.33 (S), 1.5 (T) £250 One site Nurse 3
T9 T, F, (PFI), U 1150 0.12 (S), 1 m (T) £440 Multisite Nurse 3
T10 S, (U) 974 0.6 £415 Multisite Medical doctor 4
T11* T, U, F 802 0.3 (S), 1.5 (T) £400 Multisite Nurse 3
T12* P/I 76 (I) 0.43 £202 (P), £744 (S) Multisite Nurse 5
*Each of these trusts received £50K as the award was split across the health economy by the respective Strategic Health Authority, while
the remainder trusts each received £150K.
DIPC, Director of Infection Prevention and Control; F, foundation; I, intermediate care; P, primary; PFI, private finance initiative; S, secondary;
T, tertiary; U, university.
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a technology reported in interview accounts as ‘fully
implemented’ was not verified as such during observa-
tion visits to implementation wards. A total of 20 h of
observation were completed, on average 30 min per
technology. Data collection at each site continued until
all aspects of the decision process had been accounted
for by a diverse sample of informants.
Data analysis
We analysed data using an integrated approach.31
Development of codes was initially derived from the
primary data (‘ground-up’), subsequently comple-
mented with an organising conceptual framework for
the adoption of complex health innovations.31 This
framework has been previously employed to understand
multilevel innovation adoption.32 Data analysis was
conducted in parallel to ongoing data collection to feed
emerging findings and ‘test’ these in subsequent inter-
views. The Qualitative Data Analysis computer software
package N-Vivo 8 (QSR International) was used to
systematically code the data and assist analysis, especially
in cataloguing and linking concepts and codes. In line
with recommendations by qualitative method-
ologists,33e35 Yiannis Kyratsis (author 1) and Raheelah
Ahmad (author 2) independently coded all data. The
three authors met to review discrepancies,31 enhancing
internal validity.35e37 Comparative cases were analysed in
two stages: first each of the technologies within each
trust, producing individual trust case studies; second,
a comparative analysis across the trusts. Summary tables
were used to reduce the volume of primary data and to
make analytical inferences by comparing and contrasting
pairs and groups of cases.26 We defined the outcomes of
the technology adoption process as follows: ‘successful
adoption’dthe organisational executive decision to
make full use of a technology, which results in procure-
ment; ‘successful implementation’dthe technology is
put into use and operationalised.
MAIN FINDINGS
The organisational innovation process and outcomes
Of the 38 organisational technology adoption decisions
made during the period of the study, 22 technologies
were successfully adopted and implemented, while 12
were discontinued after initial adoption or only partially
implemented (table 2). There was no clear outcome
within the time frame of the study for four technologies.
The nature of technologies is described in detail else-
where.25 A general typology of technologies isolated
from context did not provide insights to likelihood of
adoption. As illustrated in table 2, the same technologies
(ie, the Hydrogen Peroxide Vapour System or the ATP
Hygiene Monitoring System) in diverse trusts and at
different stages of the innovation process resulted in
differential outcomes. Most informants reported that
they went through a series of evaluations, choices and
actions over time as the adopting trusts principally
engaged in a problem-solving exercise. The process was
dynamic, iterative and not always linear. The IPC team
and some wider staff were involved in adoption deci-
sions. While the formal executive decision lay with the
DIPCs, they were not always the key decision makers
across the cases. The size and professional composition
of the IPC teams, and the professional background of
the DIPC (table 1), varied. We found that the majority of
technology decisions were led by a perceived needdan
area of priority in IPC had been identified by trusts first
and then relevant technologies were sought (‘need
pull’). A minority of technology adoption decisions were
characterised by selecting a technology in the first
instance and exploring how this might fit with strategic
plans and service needs (‘technology push’).
Use of innovation knowledge in the organisational setting
Trusts variably accessed and prioritised the three types of
innovation knowledge in the organisational setting, and
these comprised a much broader, multidimensional
definition compared with a simpler definition when the
potential user is an individual.15 Under ‘awareness’
knowledge, the trusts considered the range of technol-
ogies available to address a particular problem, as well as
key features and potential cost implications of such
technologies. In seeking ‘principles’ knowledge, the
trusts sought primarily evidence of the technologies’
technical efficacy based on the scientific principles
behind the technology. They assessed the validity of
claims made by commercial suppliers. In the ‘how-to’
knowledge, the trusts sought knowledge about the
practical application of the technologies in local
healthcare settings with nine trusts trialling the tech-
nologies. This included users’ experience with the
technologies, aesthetics, functionality as well as compat-
ibility with strategic, structural and cultural elements of
the trust’s context. A more detailed estimation of the
short-term and long-term associated costs also consti-
tuted ‘how-to’ knowledge. Cost and effectiveness issues
permeated the three types of innovation knowledge. The
definition of effectiveness was broader when both ‘princi-
ples’ and ‘how-to’ knowledge were given sufficient
attention and this ranged from local opinion, including
patient perceptions, ease of use by staff, to experimental
controlled trials data. The majority of informants from
all trusts noted that no particular technology could be
solely or directly attributable to reducing HCAIs, and
impact was attributable to ongoing multifaceted
approaches.
Centralised and local dissemination of innovation
knowledge
Those involved in decisions used a wide range of sources
to get information on the three types of innovation
knowledge (table 3). Peer review journals and commer-
cial suppliers were used in all trusts to source ‘principles’
knowledge. Supplier information was reported as
compact and easy to access for practitioners; however,
this source was viewed as less credible. Of the
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government-funded centralised evidence dissemination
structures, DH Showcase Hospitals Programme was
widely used by trusts for obtaining ‘awareness’ and ‘how-
to’ knowledge, but none of the trusts used it for ‘prin-
ciples’ knowledge. Local expert advice was preferred to
the dedicated central expert panel (Rapid Review Panel)
for obtaining ‘principles’ knowledge, while guidelines
were used by only three trusts. Professional networks
consistently featured among the top sources for all three
types of innovation knowledge. The latter were used to
exchange experiences on the use of the same or similar
technologies, spreading information horizontally via
networks of peers and local experts.
Critical timing of innovation knowledge use
We found that at the earlier stages of the process,
‘principles’ knowledge was given more attention over-
looking important aspects of ‘how-to’ knowledge. When
‘how-to’ knowledge was considered late, there were
negative implications for the adoption and imple-
mentation of the technologies (table 2). For example,
‘how-to’ knowledge was not considered early on in Trust
Table 2 The stage when ‘how-to’ knowledge was first considered in the process and associated outcome
Initiation Adoption decision Implementation
Infection Manager Software (T6)/
Successful adoption and implementation
Smart flat infection control computer
keyboard and mouse (T8)/
Technology modification and
subsequent successful implementation
Hydrogen Peroxide Vapour System
(T9)/Incomplete implementation
Urinary Catheter Care Bundle (T1)/
Successful adoption and implementation
Hydrogen Peroxide Vapour System
(T7)/Implementation trial informed
disinvestment
Ultrasonic cleaning tanks (T5)/
Discontinued adoption of the
technology
Endoscopy sinks (T2)/Successful
adoption and implementation
Ozone Sanitizer Machines (T9)/
Successful adoption and
implementation in one of the two
hospital sites/not implemented in
second site
ATP Hygiene Monitoring System
(T9)/Discontinued adoption of
the technology
Real-time PCR for Norovirus testing
(T2)/Successful adoption and
implementation
Antiseptic Body Cleaning Washcloths
2% Chlorhexidine Gluconate (T10,
T11)/Implementation trial informed
disinvestment (T10)/‘controlled and
focused’ use (T11)
Ultraviolet (UV) light air sterilisation
units (T4)/Discontinued adoption
of the technology
Hydrogen Peroxide Vapour System
(T12)/Successful adoption and
implementation
Infection control IT surveillance system
(T3)/Delayed adoption and very
delayed/incomplete implementation
Faecal management system (T10)/
Discontinued adoption of the
technology
ATP Hygiene Monitoring System
(T11, T12)/Successful adoption
and implementation
Hydrogen Peroxide Vapour System
(T6)/Successful adoption and
implementation
ATP Hygiene Monitoring System
(T4)/Incomplete implementation
Microbiology testing: mass
spectrometry analysis machine
(T5)/Successful adoption and
implementation
ATP Hygiene Monitoring System
(T5, T10)/Evaluation trial informed
procurement and successful trust-wide
implementation
Non-chlorine disinfectant (T10)/
Discontinued adoption of the
technology
Digital Count up posters/boards
(T8)/Successful adoption and
implementation
Hand signage (T2)/Successful
adoption and implementation
PCR for MRSA testing (T2)/
Delayed implementation
Portable PC Tablets (T6, T8)/
Successful adoption and
implementation
Chlorhexidine Gluconate dressing
(disk) to prevent Catheter-Related
Blood Stream Infections (T4)/
Incomplete implementation
Individual Patients MRSA
Decolonisation Pack (T11)/
Successful adoption and
implementation
UV light inspection units (T11)/
Discontinued adoption of the
technology
Single use disposable Blood Pressure
Cuffs and Pulse Oximeter Probes
(T7)/Successful adoption and
implementation
UV light hand inspection kit (T12)/
Successful adoption and
implementation
NB, Four technologies are excluded in the table as there were no clear outcomes within the time frame of the study.
MRSA, meticillin-resistant Staphylococcus aureus.
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4 for the ultraviolet light air sterilisation units, and
consequently, the technology was discontinued after
initial adoption. Hidden running costs, such as replacing
costly bulbs and filters regularly, as well as the practicality
of assembling units on site, were overlooked. Conversely,
when ‘how-to’ knowledge was considered earlier by
decision makers, successful technology adoption and
implementation was evident. The 14 technology cases
for which ‘how-to’ knowledge was first considered
during the ‘initiation’ stage were all adopted and
implemented successfully. The 10 technology cases for
which ‘how-to’ knowledge was first considered during
the ‘adoption decision’ stage, mainly during pre-adop-
tion evaluation trial, resulted in informed organisational
decisions to either adopt or reject technologies; and
for those technologies adopted led to subsequent
successful implementation. For the 10 technology cases
where ‘how-to’ knowledge was first considered during
‘implementation’, uptake was challenging leading to
unsuccessful implementation following initial adoption.
Looking in more detail at an example where ‘how-to’
knowledge was inadequately considered in the early
stages of the process is that of ultrasonic cleaning tanks
in Trust 5:
[the technology] was very definitely sold as a replacement
for manual cleaning.we embarked in the belief that
using the tank would mean that when the equipment
came out at the other end and was dried it would be safe
to use on the next patient.we didn’t feel comfortable
[after having tested the tanks for bacteria levels in water
after cleaning] and we felt that to make these pieces of
equipment safe we would then manually go over them
with a disinfectant.and this means additional workload
[Senior IPC Nurse]
Important aspects of structural incompatibility only
came to light during implementation. The water in the
tanks needed to be replaced after each cleaning session,
refilled and water heated overnight. This added to the
hospital staff workload. The tanks needed to be hardwired
for electricity, which meant no manoeuvrabilitydthe
initial plan had been to move the tanks around
the hospital rather than shift dirty and bulky items to the
tanks. The technology though purchased by the trust,
resulted in becoming obsolete; the tanks were housed by
estates in a storage area on the top floor of the hospital
and used in a very different way from the original plan.
An example where detailed attention was given to
‘how-to’ knowledge during the ‘adoption decision’ stage
informed subsequent purchases of infection control
computer keyboards and mice (fully enclosed and flat
design enabling quick and thorough cleaning) used with
Picture Archiving and Communication Systems in clin-
ical areas. In Trust 8, feedback from chest consultants
(principal users of the technology) resulted in appro-
priate procurement of computer devices, which were
consistent with working practices as well as compliant
with infection prevention guidelines:
Had we not changed [the newly introduced] flat
computer mouse to replace it with one that has got
a push scrolling button, the targeted users would not
have used it at all; it is highly likely that they would have
Table 3 Type and sources of innovation knowledge used in the technology adoption process per trust
Types of innovation
knowledge
Awareness knowledge:
identify technologies
available to specific IPC
priority areas and
information about the
nature of these
technologies
Principles knowledge: why
and how a technology
works in terms of the
underlying scientific
principles or theory
‘How-to’ knowledge: how to
put the technology in use,
including issues of
compatibility with trust
structures/strategy/culture
and issues of sustainability
Sources of innovation
knowledge
Professional networks/other
NHS trusts
n¼11 n¼7 n¼10
Peer review journals n¼2 n¼12 e
Hospitals outside UK n¼1 e e
Commercial supplier n¼6 n¼12 n¼11
Previous experience of
other technologies
e e n¼5
Previous experience of
same/similar technology
n¼6 e n¼6
Showcase Hospitals
Programme
n¼7 e n¼8
Rapid Review Panel (RRP1) n¼7 n¼1 e
Expert advice n¼7 n¼4 e
Own research/evaluation trial e n¼2 n¼3
DH disseminationd
conferences, websites
n¼5 n¼1 e
Internet n¼1 e e
Guidelines e n¼3 e
n, number of trusts (out of a total population of 12 trusts studied).
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replaced them with normal computer mouse instead.
[Trust 8]
The influence of professional background and organisational
type
We found variation in the priority given to the type of
innovation knowledge across professional groups. Nurse
professionals involved in adoption decisions reported
taking an approach where careful focus on ‘principles’
knowledge was balanced with adequate attention to
‘how-to’ knowledge. Conversely, medical professionals
always prioritised ‘principles’ knowledge. Consistently
across the trusts, consultant microbiologists, clinical
matrons and infection control nurses looked at the same
technologies differently and came to divergent decisions
regarding the value of specific technologies. Specifically
in T4, T6, T7, T10, T11, the clinical microbiologists
valued almost exclusively ‘principles’ knowledge to judge
the effectiveness and appropriateness of technologies for
the trusts. Clinical microbiologists across trusts, looked
primarily at peer-reviewed published articles for such
information. In contrast, clinical matrons preferred
more applied information about technology effective-
ness and would discount solely technical accounts, as the
following quote illustrates:
“You don’t want such jargonistic information. You need
to make it very simple to say this is how it works. These are
the benefits, blah, blah, blah, rather than going to such,
you know, higher level of microbiology” [Clinical
Matron].
An IPC nurse in the same trust highlighted the
importance of combining ‘how-to’ and ‘principles’
knowledge to assess effectiveness and appropriateness of
the technologies:
You need both evidence from [peer review] papers and
the practicality of using the product [in the local
context]. It’s very important [IPC Nurse].
Trusts affiliated with universities, comprising research
active organisations (T3, T4, T5, T8, T10, T11dalso see
table 1), prioritised and systematically searched for
scientifically produced ‘principles’ knowledge. This
attitude was mirrored across professional groups, though
was more pronounced in accounts by respondents from
the medical profession.
DISCUSSION
Main findings
We found the technology adoption process to be highly
dynamic and iterative. Adoption decisions entailed the
acquisition and processing of new knowledge by organ-
isational members who sought to reduce uncertainty
about an innovation. Trying to find solutions to prob-
lems was the key motivator for sourcing evidence across
the cases.
Scientifically produced ‘principles’ knowledge was
prioritised by those involved in decisions to judge
effectiveness of technologies. Empirical and experiential
types of knowing were also widely used to judge the
effectiveness and appropriateness of the technologies in the
local setting but were often assessed later in the process.
This late consideration of ‘how-to’ knowledge had
implications for successful adoption and implementa-
tion. In the cases where ‘how-to’ knowledge was given
least priority during the early stages of ‘initiation’ and
‘adoption decision’, issues that should have been picked
up when adoption decisions were being made came up
at implementation trial and even once trust-wide
implementation had begun. This resulted in (a)
increased likelihood of technology rejection or
protracted procurement decision at the ‘adoption deci-
sion’ stage, (b) delayed or incomplete implementation
or discontinuance (following initial adoption) during
the stage of ‘implementation’.
Commercial suppliers and peer review publications
were used as often as each other for ‘principles’ knowl-
edge while noting potential supplier bias. Suppliers
responded to preferences for theoretical knowledge by
a highly professionalised user group. This is in contrast
to individual consumers where marketing, as well as
consumer interest is focused on ‘awareness’ and ‘how-to’
knowledge.15 Centralised (health system) structures
were particularly underused as sources for ‘principles’
knowledge and were reported as less accessible and less
relevant to the local context. Professional networks were
widely used and comprised practice-based peer-mediated
information about the innovations’ relevance to the
local setting.
The priority given to the three types of innovation
knowledge depended on: (a) type of trustdteaching
hospitals or research active organisations prioritised
‘principles’ knowledge; (b) professional background of
those involved in adoption decisionsdmembers of the
medical profession tended to prioritise ‘principles’ and
often ignored ‘how-to’ knowledge, while members of
the nursing profession tended to balance the use of
‘principles’ and ‘how-to’ knowledge.
Strengths and weaknesses
The scale of the study and the real-time nature of
investigating 38 adoption and implementation processes
over a period of 18 months provided a rich data set. Our
study is theory driven and comprises multisite compar-
ative case studies, which overall enhance the general-
isability of findings beyond the context of the specific
sites studied.27 We explicitly studied cases of non-adop-
tion and discontinuation after initial adoption, which
are rarely included in innovation diffusion studies. We
looked at centralised, organisational, professional and
local influences in the process.
On limitations, the predefined sample in our study was
not exhaustive by trust type, though sufficiently diverse
(table 1). At the same time, a common barrier to
adoption (availability of funding) was ‘controlled for’ in
this sample, allowing other factors during adoption
decision to be explored. We were not able to follow
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implementation past the end of August 2010 and
therefore do not have information on routinised use of
the implemented technologies.
Important differences in results with other studies
While innovation literature in commercial sectors
considers the types of innovation knowledge in tech-
nology adoption by individuals,15 the role of these types
of knowledge in organisational decisions within the
highly professionalised context of a healthcare system is
missing. The types of trusts, and the professional back-
ground of those involved in technology adoption deci-
sions influenced how technologies were adopted and
implemented in our study. These factors had bearing
on the type of innovation knowledge used and timing of
this knowledge utilisation. These findings build on liter-
ature that identifies interactions between the innovation,
local actors, leadership and multilevel contextual factors10
12 38e40 shaping the technology adoption process.
Furthermore, our study demonstrates an impact of vari-
able use of knowledge on ‘successful’ adoption decisions.
The role of professional backgrounds in this process
builds on work by Ferlie and colleagues5 who looked at
the adoption of guidelines in four areas of clinical care
and found that there are cognitive, social and epistemic
barriers to knowledge flow among health professionals.
Data from all cases show that ‘how-to’ knowledge was
important in the innovation process, not only opera-
tionally but also strategically, spanning issues of struc-
tural and cultural compatibility, and sustainability. This
broader conceptualisation better aligns the construct
with the complex adjustments that are often needed in
organisational settings.6 29 Our findings suggest a more
prominent focus for ‘how-to’ knowledge in the future, by
both practitioners and researchers.41 42
Implications for clinicians and policymakers
Health systems remain to fully exploit patient benefit
through sustainable use of evidence-based technolo-
gies.43 44 Balancing ‘principles’ and ‘how-to’ knowledge
at the early stages of the innovation process will provide
decision makers with clinical and financial justification
for innovations, as well as practical implementation
guidance. Learning from discontinued adoption or
failed implementation of technologies is as important as
success stories.
Data from all our cases show that acceptance of
innovation knowledge depended on the perceived
credibility of the source. Current health policy practice,
as outlined in the introduction, is implicitly founded on
the notion that health professionals do access primarily
centralised sources to acquire knowledge about innova-
tive technologies. Our findings differ, emphasising
a more prominent role of local and peer-mediated
sources, such as professional associations, local practice
trials, experiences of peers and local experts. Given the
patterns of knowledge exchange among our respon-
dents, investing in horizontal knowledge exchange to
complement ‘top down’ knowledge transfer is indicated.
Appraising the local environment for structural and
cultural compatibility of the technologies is essential
along with evidence for efficacy and cost-effectiveness to
avoid waste of valuable resources and potential to cause
inadvertent harm from inappropriate implementation.
There are implications here of who is involved in the
innovation adoption process and the role played by key
decision makers. Since healthcare services are increas-
ingly configured as multiprofessional team activities45
organisational innovation adoption decisions need also
to account for local attitudes to evidence of different
professional groups. Policy makers need to reconcile the
need for central guidance and quality standards with
locally relevant practice-based evidence to contextualise
the research in line with practical needs.
Future research and unanswered questions
More work is needed to understand how organisational
priorities shape the perspective of organisational leaders
and other key decision makers as regards innovation
knowledge. In particular, a better understanding of the
dynamics in the late stages of the innovation process in
organisations (implementation and routinisation) is
needed. A study in progress funded by National Institute
for Health Research Service Delivery & Organisation
(NIHR SDO) considers such issues in depth.46
A number of other questions remain unanswered.
Future studies need to account for individual and
organisational motivation to source evidence. Also, given
that different professionals view different sources and
types of evidence differently, how can these differences
be reconciled? And who can play the role of ‘evidence
broker’? Finally, we need to account for wider influences
of different health system structures (centralised tax
based versus disaggregated ‘market’ systems) and how
these shape use of evidence and, ultimately, innovation
uptake.
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